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Abstract
Isocyanates have been a leading chemical cause of occupational asthma since their utility for 
generating polyurethane was first recognized over 60 years ago, yet the mechanisms of isocyanate 
asthma pathogenesis remain unclear. The present study provides in vivo evidence that a GSH 
mediated pathway underlies asthma-like eosinophilic inflammatory responses to respiratory tract 
isocyanate exposure. In naïve mice, a mixture of GSH reaction products with the chemical 
allergen, methylene-diphenyl diisocyanate (MDI), induced innate immune responses, 
characterized by significantly increased airway levels of Chitinase YM-1 and IL-12/IL-23β (but 
not α) subunit. However, in mice immunologically sensitized to MDI via prior skin exposure, 
identical GSH–MDI doses induced substantially greater inflammatory responses, including 
significantly increased airway eosinophil numbers and mucus production, along with IL-12/
IL-23β, chitinases, and other indicators of alternative macrophage activation. The “self”-protein 
albumin in mouse airway fluid was uniquely modified by GSH–MDI at position 414K, a preferred 
site of MDI reactivity on human albumin. The 414K–MDI conjugation appears to covalently cross-
link GSH to albumin via GSH's NH2-terminus, a unique conformation possibly resulting from 
cyclized mono(GSH)–MDI or asymmetric (S,N′-linked) bis(GSH)–MDI conjugates. Together, the 
data support a possible thiol mediated transcarbamoylating mechanism linking MDI exposure to 
pathogenic eosinophilic inflammatory responses.
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Isocyanates (N=C=O) are reactive chemicals with many commercial/industrial uses, 
especially the di- and poly isocyanates essential to polyurethane production.1 Adverse 
respiratory health effects from isocyanate exposure were first reported in 1951, yet global 
production and usage continues to increase with economic demand for polyurethane 
products.2 Methylene-diphenyl diisocyanate (MDI) is the most abundantly produced 
isocyanate, with specialized applications for making rigid foams, including spray 
polyurethane foam insulation.3,4 Despite widespread recognition of MDI and other 
isocyanates' toxicity and regulation of permissible workplace airborne levels, these 
chemicals remain among the leading chemical causes of occupational asthma throughout the 
world.5,6
The mechanisms by which isocyanates cause asthma remain unclear, hampering disease 
prevention, diagnosis, and treatment.7 It is assumed the reactive nature of N=C=O groups 
underlies isocyanate asthma, with a hapten-based mechanism as the most obvious pathway 
to pathogenesis.8 However, the critical “self” reaction targets for isocyanate in vivo remain 
uncertain. Free primary amine groups on specific lysine side chains of albumin are preferred 
reactants under physiologic conditions, and isocyanate–albumin adducts can be found 
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circulating in peripheral blood of exposed workers.7,9–11 Antibodies triggered by isocyanate 
exposure specifically recognize isocyanate conjugated albumin but not other carrier proteins, 
suggesting that albumin is the major reaction target for isocyanate in vivo.8,10,12 However, 
isocyanate–albumin specific IgE antibodies are commonly undetectable among 
hypersensitive individuals, questioning the mechanistic role of albumin in isocyanate asthma 
pathogenesis.7,13
Accumulating evidence suggests free thiol groups on the tripeptide GSH, a major 
antioxidant of airway fluid, may be the primary self reactant for isocyanate in vivo.14 
Glutathione conjugation of small reactive chemicals generally comprises part of a metabolic/
detoxification pathway and may be especially relevant to isocyanates since they can react 
directly with GSH without the transferase enzymes typically required for conjugation.15–19 
However, S-linked bonds that orm with N=C=O are quasi-stable and strongly depend upon 
temperature and pH.20,21 Further reactivity of S-linked isocyanate with water reverses the 
thiocarbamate linkage and hydrolyzes the original N=C=O to an amine.16 In contrast, further 
reactivity of GSH-S-isocyanate with free amine groups on proteins (e.g., albumin), results in 
stable transcarbamoylation and distinct antigenic changes specifically recognized by serum 
IgG from exposed workers.18,19,22,23 Together, these data suggest a critical role for GSH in 
the response to isocyanate exposure.
We presently describe the inflammatory activity of GSH– MDI reaction products in vivo in 
the airways. The data support the proposed role of GSH as a reaction intermediate in the 




This chemical is dangerous. Methylene diphenyl diisocyanate is hazardous and is a well-
recognized immune-sensitizing chemical. Nitrile gloves, protective clothing, and goggles 
should be used for personal protection.
Reaction of GSH with MDI
Reduced glutathione, GSH (CAS no. 70-18-8) and 4,4′-methylenebis(phenyl isocyanate) or 
MDI (CAS no. 101-68-8) were from Sigma-Aldrich (St. Louis, MO) and were of ≥98.0% 
purity. GSH was reacted with MDI under conditions that yield reaction products with the 
greatest capacity to carbamoylate human albumin, among the conditions tested in previously 
published studies.18 Briefly, 50 μL of 10% (w/v) MDI in acetone from JT Baker 
(Phillipsburg, NJ) was added dropwise with stirring to 25 mL of 10 mM GSH in 200 mM 
sodium phosphate, pH 7.4. The reaction mixture was rotated end-over-end for 2 h at 37 °C 
and then centrifuged at 10 000g, 0.2 μm filtered, aliquoted, and used immediately or snap 
frozen in LN2 and stored at −80 °C until analysis could be performed.
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Reverse-Phase HPLC Analysis and Purification of GSH–MDI Reaction Products
GSH–MDI reaction products were fractionated on a Hewlett-Packard 1090 HPLC system 
equipped with an Isco model 2150 peak separator and a 1 mm × 25 cm Vydac C-18 (5 μm 
particle size, 300 Å pore size) reverse-phase column.7 The column was equilibrated, and 
samples were loaded in 98% buffer A (0.06% TFA) and 2% buffer B (0.052% TFA, 80% 
acetonitrile) and eluted by increasing buffer B to 37% over the course of 1 h, followed by a 
stepwise increase to 60% acetonitrile over the next 60 min and 98% washout after 2 h. 
Autopeak detection was based on A210, with simultaneous measurement at A245.
Skin Sensitization and Airway Exposure in Mice
Female Balb/C mice 8 weeks of age were housed under specific pathogen-free conditions, 
with automated water supply and 12 h day/night light cycles. Mice were immunologically 
sensitized to MDI via skin exposure, as previously described.24 Briefly, a region on the back 
was shaved 24 h prior to application of 50 μL of 1% (w/v) MDI in acetone or (in preliminary 
experiments, not shown) acetone alone as control. For respiratory tract exposure, 50 μL of 
GSH–MDI reaction products or control solutions (MDI reacted in solvent without GSH = 
MDI-m, GSH mock reacted without MDI = GSH-m) were delivered intranasally. All 
exposures were performed under isoflurane sedation. Mice received skin exposures on days 
0 and 7 and respiratory tract exposure on days 15, 16, 19, and 20, or in one experiment, mice 
received skin exposure on days 0, 7, and 30, followed by respiratory tract exposure on days 
61, 62, 65, and 66. All animal studies followed guidelines established in the Guide for the 
Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal 
Resources, National Research Council, and published by the National Academy Press 
[revised 1996].
Bronchoalveolar Lavage (BAL), Cell Count/Differential, and Lung Histology
BAL (3 × 0.8 mL), lung tissue samples, and peripheral blood were obtained 48 h following 
the last respiratory tract exposure, as previously described.24 BAL was centrifuged at 800g, 
and the supernatant was collected, aliquoted, and stored frozen at −20 °C. The cell pellets 
were treated with RBC lysis buffer, washed, and resuspended in PBS for cytospin and cell 
counting. Total BAL cell numbers were calculated using a hemacytometer, and differential 
counts were performed on 200 cytospun cells that had been stained with diff quick 
(Polysciences Inc.; Warrington, PA). For histology, lung tissue was perfused in situ and 
fixed in 10% buffered formalin. Tissue sections were visualized after hematoxylin/eosin or 
Periodic acid–Schiff stains. Histology slides and BAL cytospins were viewed and 
photographed on a Zeiss (Pittsburgh, PA) microscope.
Western Blot of Airway Fluid Protein
Electrophoresis and western blot of BAL fluid were performed as previously described 
using precast sodium dodecyl sulfate (SDS) acrylamide gels (4–15% gradient) from BioRad 
(Hercules, CA), under reducing or non-reducing conditions as noted, and protein transfer to 
nitrocellulose membrane.24 Nitrocellulose membranes were incubated for 2 h with mAbs or 
polyclonal antisera specific for YM-1, also known as mouse Chitinase 3-like 3, from R&D 
Systems (Minneapolis, MN), CLCA3, also known as mouse CLCA1, from Santa Cruz 
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Biotechnology, Inc. (Dallas, TX), biotin anti-mouse IL-12/IL-23 p40 from BioLegend (San 
Diego, CA), polyclonal HRP-anti-IgG Fc (Santa Cruz Biotechnology, Inc.), or biotinylated 
anti-MDI DA5 developed in our laboratory.25 After extensive washing with PBS containing 
0.05% Tween 20, strips were incubated with appropriate secondary antibody and developed 
with enhanced chemiluminescence substrate from Thermo Fisher Scientific Inc. (Rockford, 
IL).
iTRAQ Analysis
Pooled airway lavage samples were prepared for iTRAQ analysis using a CHCl3/MeOH 
precipitation after diluting each to 100 μL with water. Four hundred microliters of MeOH 
was then added and vortexed extensively prior to the addition of 100 μL of CHCl3. An 
additional 300 μL of water was added prior to vortexing and centrifuging at 14 000g for 1 
min. The top aqueous layer was removed and discarded, and an additional 400 μL of MeOH 
was added. After a 2 min centrifugation at 14 000g, the MeOH was removed without 
disturbing the pellet. The pellet was dried in a SpeedVac and dissolved in 50 μL of 0.5 M 
tetraethylammonium bicarbonate with 0.2% SDS. One hundred micrograms of each sample 
was used for labeling, which was determined based on a nanodrop measurement at A280 
versus a buffer blank. Disulfide reduction was performed by incubating with 5 mM tris(2-
carboxyethyl)phosphine at 60 °C for 1 h. Alkylation was then performed by incubating with 
20 mM methylmethanethiolsulfonate at room temperature for 10 min. Samples were 
digested using a 1:10 w/w ratio protein/trypsin and incubated at 37 °C for 16 h. Each dried 
iTRAQ label was dissolved in 50 μL of 100% isopropanol. Reporter ion tags 114 and 115 
were used to respectively label the proteins of the BAL samples from experiment 1, which 
compared control mice (MDI-m) and GSH–MDI exposed mice that had been skin exposed 
three times (see above). The 116 and 117 tags were used, respectively, in experiment 2, 
which compared MDI-m and GSH–MDI exposed mice that had received only two skin 
exposures. After vortexing, each reconstituted iTRAQ reagent was transferred to the 
appropriate vial and incubated at room temperature for 2 h. At this point, the tagged sample 
digests were mixed together and acidified with 1 M phosphoric acid to a pH less than 3.0 
and then separated on a Hewlett-Packard 1090 HPLC system fitted with a polySulfethylA 
column (The Nest Group, Southborough, MA). At 0.5 mL/min of buffer A (10 mM 
KH2PO4, pH 3.0, 25% acetonitrile), a gradient of 0–100% buffer B (10 mM KH2PO4, 1 M 
NaCl, pH 3.0, 25% acetonitrile) was established over 120 min. Fractions were collected at 1 
min intervals. The broad, unresolved A214 peak was pooled into 10 fractions according to 
absorbance.
The samples were dried, dissolved in 20 μL 70% formic acid (FA) and diluted with 300 μL 
0.1% trifluoroacetic acid (TFA), prior to desalting using a Macrospin C18 (The Nest Group 
Inc., South-borough, MA). The bound peptides were eluted with 360 μL of 80% acetonitrile 
(ACN) containing 0.1% TFA, and the elution was repeated by washing with an additional 
180 μL of the same solution. Samples were dried in a SpeedVac and dissolved in 3 μL of FA 
mixed with 8 μL of 0.1% TFA. Three micrograms of each strong cation exchange fraction 
(N = 10) was separated and analyzed on a Waters (Milford, MA) nanoAcquity UPLC system 
equipped with a 5600 TripleTOF (AB SCIEX; Framingham, MA) fitted with a Nanospray 
III source (AB SCIEX) and a pulled quartz tip as the emitter (New Objectives, Woburn, 
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MA). The Waters nanoAcquity UPLC system uses a Waters Symmetry C18, 180 μm × 20 
mm trap column, and a 1.7 μm, 75 μm × 150 mm nanoAcquity UPLC column (45 °C) for 
peptide separation of the multiplexed samples. Trapping was done at 15 μL/min, with 99% 
buffer A (99.9% water and 0.1% FA) for 1 min. Peptide separation was performed at 500 
nL/min with buffer A and buffer B (99.925% acetonitrile and 0.075% FA). The gradient was 
99% A under initial conditions with a linear gradient to 35% B at 160 min and 95% B at 
160.3 min.
The combined raw MS/MS files (*.wiff) from Analyst TF 1.6 were analyzed by Mascot and 
with the Paragon search algorithm26 of ProteinPilot (version 4.5). Data was searched against 
the SwissProt protein database (April 2014, 544 996 sequences) with a mouse taxonomy 
filter (16 676 sequences). For each ratio, the iTRAQ peak areas (for each peptide) are 
corrected for both observed bias correction and background correction. The false discovery 
analysis conducted by the ProteinPilot software utilized a reversed-sequence decoy database 
to determine the false discovery rate. Peptides identified by ProteinPilot were filtered using 
the auto setting to include only unique peptides, no missed cleavages, and at least two 
iTRAQ ions per peptide. To minimize iTRAQ ratios from low-intensity ions, ProteinPilot 
also required peptides to maintain a signal-to-noise ratio greater than 9 from the combined 
intensities of the contributing iTRAQ ions. Additionally, each protein quantified by 
ProteinPilot required two or more peptides.
Protein fold ratios were calculated and expressed from a pairwise comparison of two iTRAQ 
channels (114 vs 116 or 115 vs 117). The final ratio shown in the Yale protein expression 
database (YPED) is based on a weighted averaged of the corrected peak areas. All iTRAQ 
results were uploaded into the YPED (http://yped.med.yale.edu/repository/).27
Cytokine Protein Array and ELISAs
BAL fluid was analyzed using a cytokine antibody microarray from RayBiotech Inc. 
(Norcross GA). Pooled samples from N = 6 MDI skin sensitized mice, exposed to either 
GSH–MDI or MDI control (MDI reacted without GSH = MDI-m as described above), were 
incubated on different array membranes overnight at 4 °C. Microarrays were developed 
according to the manufactures specifications using enhanced chemiluminescence with 
substrate from Thermo Fisher Scientific Inc. and Carestream Kodak BioMax light film from 
Sigma-Aldrich. Additional cytokine analyses were performed by ELISA using kits from 
Biolegend (IL-4, IL-5, IL-10, IL-12p40, IL-23), R&D Diagnostics (IL-13, IL-12p70), or 
eBiosciences (San Diego, CA) (IL-10) and RayBiotech Inc. (IL-10) according to the 
manufacturers' recommendations.
Statistical Analyses
Statistical significance of differences in BAL cell numbers or cytokine levels was 
determined with an unpaired Student's t test or with analysis of covariance when data from 
more than one experiment were pooled.
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Glutathione–MDI (GSH–MDI) Reaction Products Induce Airway Inflammation
In vivo studies were performed in mice to determine the biological activity of GSH–MDI in 
the respiratory tract. GSH–MDI reaction products containing a mixture of bis(GSH)–MDI 
and mono(GSH)–MDI conjugates (see Supporting Information Figure S1) were delivered 
intranasally to naïve mice or mice immunologically sensitized to MDI via prior skin 
exposure as previously described.24 Mice that received GSH–MDI exhibited significantly (p 
< 0.01) greater numbers of cells in the airway and mucosal lung tissue vs mice that received 
control reaction products of GSH reacted without MDI (GSH-m) or MDI reacted without 
GSH (MDI-m, essentially hydrolyzed MDI), as shown in Figures 1 and 2. Mice that were 
immunologically sensitized to MDI exhibited exaggerated and qualitatively distinct 
inflammatory responses to GSH–MDI compared with that in naïve animals, with 
significantly (p < 0.02) greater airway eosinophilia, total cell numbers, and mucus 
production (Figures 1 and 2).
Cytokines in the Airways of GSH–MDI Exposed Mice
Inflammatory mediators induced by GSH–MDI were initially characterized by analysis of 
airway fluid samples using broad-spectrum cytokine/chemokine monoclonal antibody-based 
arrays. Data comparing immunologically sensitized mice exposed to GSH–MDI vs controls 
(Figure 3A) suggested that GSH–MDI induced substantial increases in the beta (p40) 
subunit of IL-12 but not the complete, heterodimeric (α/β) IL-12 cytokine (e.g., p70). 
Subsequent ELISA studies (Figure 3B) confirmed that both naïve and immunologically 
sensitized mice exposed to GSH–MDI had significantly (p < 0.05) elevated IL-12 beta 
airway fluid levels, without measurable increases in IL-4, IL-5, IL-12p70, IL-13, or IL-23, 
which uses the same beta (p40) subunit as IL-12.28 Western blot analysis of airway fluid 
from GSH–MDI exposed mice vs controls revealed the presence of IL-12 p40 monomers as 
well as homodimers (which are known to modulate IgE, IL-12 receptor signaling, and other 
immune responses in vivo)29,30 rather than conventional heterodimeric IL-12/IL-23 α/β 
pairings (Figure 3C).
Airway Protein Analysis Using Isobaric Tags for Relative and Absolute Quantitation 
(iTRAQ)
To better understand the GSH–MDI exposure induced changes in the airway 
microenvironment, additional proteomic analyses of airway fluid from GSH exposed mice 
were performed using iTRAQ.31 Two separate iTRAQ experiments of pooled airway fluid, 
from sensitized mice exposed to GSH–MDI vs control animals, identified the greatest 
average differences in the 25 proteins listed in Table 1. The protein most increased in the 
airways of MDI sensitized, GSH–MDI exposed animals was CLCA1, also known as gob-5, 
which induces mucus production.32 Western blot analyses (Figure 4) confirmed the increase 
in glycosylated full-length CLCA1 (∼130 kDa)33 levels in airway fluid of GSH–MDI 
exposed mice previously sensitized to MDI, but not naïve animals, consistent with histology 
data shown in Figure 2. The second, third, and fourth most increased proteins in airways of 
MDI sensitized, GSH–MDI exposed mice are well-described biomarkers of alternatively 
activated macrophages (chitinases YM-1 and YM-2 and RELMα/Fizz1).34 Western blot 
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analyses (Figure 4) verified that airway fluid YM-1 levels were increased in both naïve and 
MDI immune sensitized mice upon GSH–MDI exposure. A number of additional proteins 
upregulated in MDI sensitized, GSH–MDI exposed mice are known to have specialized 
roles in the immune system and/or have been linked to human asthma.35
A limited number of proteins were consistently decreased (>2-fold) in the BAL fluid of MDI 
sensitized, GSH–MDI exposed vs control mice (Table 1). The most underrepresented 
proteins (>3.4-fold decreased) were indolethylamine N-methyltransferase (INMT), a major 
lung N-methyltransferase that inactivates histamine in vivo,36 and DNA repair enzyme 
XRCC1 (>2.4-fold decreased), which is underexpressed in monocytes.37 Other airway fluid 
proteins reduced 2-fold below control levels included PLUNC-1, Napsin A, Filamin, 
carboxypeptidase M, and a particular transmembrane protease (TMPSD). The significance 
of these proteins' underexpression in GSH–MDI induced airway inflammation remains 
unclear at the present time.
MDI Conjugated Albumin in GSH–MDI Exposed Mice: Evidence of Transcarbamoylation in 
Vivo
One mechanism through which GSH–MDI might mediate airway inflammation is 
transcarbamoylation, or transfer of MDI, from the unstable S-linkage with GSH to a stable 
N-linkage with a protein. Transcarbamoylation may alter a protein's conformation, thereby 
creating new antigens (neoepitopes) recognized as foreign by the immune system,18 or it 
could alter protein function in a way that evokes inflammation. To begin assessing this 
possibility, we probed for MDI modification of host airway fluid proteins by western blot 
using an anti-MDI mAb (Figure 5A). The data identified a single major MDI-conjugated 
airway fluid protein in GSH–MDI exposed mice, with an apparent molecular weight (∼68 
kDa) consistent with that of mouse albumin.38 Retrospective reanalysis of mass 
spectrometry data from the iTRAQ experiments (above) further supported MDI conjugation 
of airway fluid mouse albumin (see Supporting Information Tables S1 and S2). When the 
data were queried for the 614 Da modification due to transcarbamoylation by GSH–MDI 
and subsequent carbamidomethylation during the mass spec sample workup, as previously 
described in vitro,18 a single peptide was uniquely identified in GSH–MDI exposed vs 
control animals' BAL. The data identify in vivo modification of mouse albumin on the 
lysine residue at position 414 of the mature protein, a preferential MDI conjugation site of 
human albumin in vitro.9,18 As depicted in Figure 5B and supported by MS/MS data (Figure 
S2), the albumin-Lys414 appears to be cross-linked via one MDI molecule to the NH2-
terminus of GSH (e.g., via γ-glutamate), a configuration also described for HDI in vitro.19 
The observed modification could result from reactivity with cyclized mono(GSH)–MDI, 
asymmetric (S,N′-linked) bis-(GSH)–MDI, or via intramolecular rearrangement, before or 
after, reactivity with the symmetric (S,S′-linked) bis(GSH)– MDI. Together, the data support 
the hypothetical role for GSH in mediating the modification of self proteins, leading to 
subsequent airway inflammation and asthma.
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The present data define a possible thiol mediated biochemical link between occupational 
exposure to the chemical allergen, MDI, and asthma-like airway inflammation in vivo. The 
tripeptide, glutathione, which is normally present at high levels (>100 μM) in the airway 
fluid,14 reacts rapidly with MDI under physiologic conditions, resulting in a mixture of 
mono(GSH)– MDI and bis(GSH)–MDI conjugates. These GSH–MDI reaction products 
transcarbamoylate host proteins and induce localized innate immune responses in the 
airway. In mice immunologically sensitized to MDI via prior skin exposure, GSH–MDI 
induces significantly greater airway eosinophilia and mucus production, two pathological 
hallmarks of asthma. Local airway inflammatory response to GSH–MDI are characterized 
by markers of alternative macrophage activation and selective increases in the shared beta 
subunit of IL-12/IL-23 but not in the respective alpha subunits or other asthma-associated 
Th2-type cytokines (IL-4, IL-5, IL-13). Together, the findings describe a glutathione 
mediated pathway that may distinguish the pathogenesis of isocyanate asthma from that 
triggered by other allergens. The findings may explain some of the puzzling characteristics 
of isocyanate asthma that challenge disease recognition and prevention and may extend to 
airway diseases caused by other reactive chemicals.
A glutathione mediated transcarbamoylation mechanism, as described above, could drive 
potentially distinct pathways of immune activation vs direct isocyanate reactivity 
(nucleophilic addition) with host molecules. Glutathione conjugation with isocyanate would 
protect the parent chemical from hydrolysis or conjugation with protective barrier 
molecules, allowing deeper penetration into lung tissue and reactivity with host molecules 
otherwise sheltered from isocyanate by their microenvironment. In addition to causing MDI 
modifications identical to those produced by direct nucleophilic addition with MDI, 
transcarbamoylation of proteins via GSH–MDI can produce additional unique epitopes, 
whose clinical significance remains to be tested. Most importantly, however, GSH mediated 
carbamoylation could cause functional (vs structural/antigenic) changes in host proteins that 
trigger airway inflammation without evoking chemical-specific adaptive immune responses, 
such as isocyanate-specific IgE.
In the present study, a single mouse airway fluid protein, albumin, was detectably 
carbamoylated by GSH–MDI, at a single loci (Lys414), the same site previously identified as 
a preferential isocyanate target on human albumin in vitro.9,18 The Lys414 modification 
consisted of covalent linkage to a MDI molecule that was capped by the γ-glutamate of 
GSH, which, to the best of our knowledge, represents a previously undescribed in vivo 
protein modification. The data are consistent with clinical investigations suggesting albumin 
as the major carrier protein for isocyanate in occupationally exposed workers,8,12 but they 
do not rule out the possibility that additional targets of GSH mediated carbamoylation exist 
in the airway epithelial tissue.39
Consistent with potentially distinct mechanisms of isocyanate induced pathogenesis, the 
inflamed airways of MDI sensitized, GSH–MDI exposed mice contained strikingly different 
cytokine profiles vs that observed in prototypical mouse asthma models (e.g., ovalbumin).40 
Rather than T-cell derived cytokines (IL-4, IL-5, and IL-13), GSH–MDI increased the 
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shared IL-12/IL-23β (but not α) subunit, which is produced largely by macrophages/
dendritic cells and, to a lesser extent, B-cells.41 IL-12/IL-23β monomers and dimers have 
biological activity distinct from IL-12 or IL-23 α/β hetrodimers, including macrophage 
chemoattraction and the ability to counter-regulate IL-12 activity.29,30,41,42 Moreover, IL-12 
signaling plays a critical role in regulating IgE production, which is further modified by 
genetic polymorphisms and unusual RNA editing of IL-12 receptor transcript. 43,44 Thus, 
the IL-12 axis may play a more prominent role in isocyanate asthma vs that induced by other 
allergens and could help to explain the paradoxical lack of isocyanate-specific and/or low 
total IgE levels in isocyanate-hypersensitive individuals.
In addition to distinct cytokines, another striking feature of the GSH–MDI induced airway 
inflammatory response was the prominent protein profile of alternatively activated 
macrophages (AAMs), including three of the four proteins most increased in the airway 
fluid (YM-1, YM-2, and RELMα/Fizz1). GSH–MDI induction of murine AAMs in vivo is 
consistent with previous in vitro studies demonstrating isocyanate induced activation of 
human macrophages, including chitinase upregulation and associations of monocyte-derived 
cytokines with clinical response to respiratory tract exposure.45–48 The in vitro human 
response to isocyanate, like the present in vivo murine response to GSH–MDI, occurs 
without measurable increases in critical cytokines (IL-4/IL-13) known to polarize monocyte 
responses34 and may define novel pathways by which macrophages are alternatively 
activated.
Besides YM-1, YM-2, and RELMα/Fizz1, a number of other airway proteins were markedly 
affected by GSH–MDI exposure. The most upregulated proteins included molecules 
previously associated with asthma (CLCA1 or gob-5, VCAM1, CTSS) and specific 
components of the mucosal/IgA immune system (IgA constant region, and nonpolymorphic 
H-2 class I-Q10a). The two most downregulated proteins (XRCC1 and INMT) are thought 
to function in repairing or limiting tissue damage, specifically that involving single-strand 
DNA breaks, xenobiotics, or endogenous amino, sulfo, or selenium compounds.36,37 
Overall, the protein changes in the airways of sensitized, GSH–MDI exposed mice are 
distinct compared with those induced by other respiratory tract exposures49–51 and might 
serve as biomarkers of MDI exposure and/or asthma.
The relationship of the exposure doses used in this study to human exposure levels in 
occupational settings is crucial to interpreting the potential clinical relevance of the present 
findings. The 1% MDI (w/v) skin exposure dose, used for inducing systemic immune 
sensitization, is roughly equivalent to the final MDI concentration in polyol/diisocyanate 
mixtures used to make polyurethane foam.1 The GSH–MDI dose delivered via the intranasal 
route is more challenging to compare with human occupational respiratory tract MDI 
(vapor/aerosol) exposure, due to uncertainty regarding the relative rates of GSH–MDI 
formation and hydrolysis, and requires some extrapolation. On the basis of the amount of 
MDI used to make the GSH–MDI starting material (assuming 100% GSH–MDI product 
formation and subsequent release of active MDI), each intranasal exposure delivered the 
potential equivalent of 10 μg of MDI, approximately 100-fold below the predicted inhaled 
MDI dose (1 mg) for a human during an 8 h work shift, if exposed to MDI vapor/aerosol at 
the permissible exposure limit established by the U.S. Occupational Health and Safety 
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Administration (0.2 mg/m3), assuming a mean minute ventilation rate ranging between 10 
and 20 L/min.52–56
In summary, this article provides evidence that isocyanate– glutathione reaction products 
could play a unique role in the pathogenesis of isocyanate asthma and may help to explain 
some of the unusual features of the disease. The findings confirm the rapid, spontaneous 
reactivity of GSH with MDI under physiological conditions and further demonstrate the 
ability of GSH–MDI to carbamoylate self proteins in vivo and trigger airway eosinophilia 
and mucus production. The cytokines and alternative pattern of macrophage activation 
observed in response to GSH–MDI suggest these reaction products may trigger distinct 
signaling cascades vs conventional asthma-causing allergens. Together, the data provide 
proof-of-principle that GSH can mediate pathogenic responses to respiratory tract MDI 
exposure in vivo and suggest that GSH, or functionally related thiols, might represent targets 
for disease prevention and/or intervention.
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Abbreviations
BAL bronchoalveolar lavage
CLCA1 aka gob-5 calcium activated chloride channel regulator 1
CHIL3 aka YM-1 chitinase-like protein 3
CHIL4 aka YM-2 chitinase-like protein 4
GSH reduced glutathione
INMT indolethylamine N-methyltransferase
iTRAQ isobaric tags for relative and absolute quantitation
MDI methylene diphenyl diisocyanate
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RELMα aka Fizz-1 resistin-like alpha
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Airway inflammation evoked by GSH–MDI reaction products. Cytospun, stained airway 
lavage cells from representative naïve (a, b) or MDI sensitized mice (c, d) exposed via the 
respiratory tract to control stimuli [GSH-m = GSH reacted without MDI (a); MDI-m = MDI 
reacted without GSH (c)] or GSH–MDI reaction products (b, d). Asterisks highlight 
eosinophils, and arrows highlight neutrophils or lymphocytes. (e) Mean number of cells 
(×10−3) ± standard error (Y-axis) derived from airway lavage samples of naïve or MDI 
sensitized mice exposed to control stimuli, GSH-m, MDI-m, or GSH–MDI. Data are derived 
from three separate experiments with a total of N = 18 mice/group.
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Lung tissue inflammation and mucus production evoked by GSH–MDI reaction products. 
Lung tissue sections from naïve mice exposed to control stimuli, GSH-m (a), or GSH–MDI 
(b) or from MDI sensitized mice exposed to control stimuli, MDI-m (c), or GSH– MDI (d) 
were subject to periodic acid–Schiff (PAS) staining to highlight mucus production (airways 
with asterisk). (e) PAS stained lung tissue section from a representative MDI sensitized, 
GSH–MDI exposed host under higher magnification to highlight the mucus containing 
goblet cells lining the airways and submucosal eosinophils.
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GSH–MDI increases airway levels of IL-12/IL-23β. (a) Monoclonal antibody-based array 
(key to the left) was used to screen for changes in cytokine levels of pooled airway fluid 
samples (N = 6 each) from MDI sensitized hosts exposed to control stimuli MDI-m (MDI 
reacted without GSH) vs GSH–MDI (middle and far right respectively). (b) Graph 
representing the mean concentration in pg/ mL ± standard error of different cytokines in 
airway fluid (Y-axis) from N = 18 each naïve or MDI sensitized mice from three separate 
experiments, exposed to GSH–MDI or control stimuli, as labeled. (c) Anti-IL-12/IL-23β 
western blot on airway fluid from naïve or MDI sensitized mice exposed to GSH–MDI or 
control stimuli (GSH-m = GSH reacted without MDI; MDI-m = MDI reacted without GSH) 
was performed under nonreducing conditions. Arrows highlight banding due to monomeric 
p40 (lower) and homodimeric p80 (upper) IL-12/ IL-23β.
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GSH–MDI increases airway chitinase YM-1 and calcium-activated chloride channel 
CLCA1. Pooled airway fluid from N = 6 naïve or MDI sensitized mice exposed to GSH–
MDI (+) or control stimuli GSH-m (−) for naïve or MDI-m for sensitized mice were western 
blotted under reducing (YM-1, IgG Fc) or nonreducing conditions (CLCA1). Arrows 
highlight the 39 kDa band corresponding to YM-1, the ∼130 kDa mature glycosylated 
CLCA1, and the ∼50 kDa heavy chain of IgG, as a loading control.
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Modification of airway fluid albumin by GSH–MDI in vivo. (a) Pooled airway fluid samples 
from N = 6 each naïve or MDI sensitized mice exposed to GSH–MDI (+) or control stimuli 
(−), GSH-m and MDI-m, respectively, were subject to reducing SDS-PAGE and western 
blotted with biotin labeled MDI-specific mAb DA5. Arrow highlights dominant band ∼68 
kDa. (b) Chemical structure depicting the unique GSH–MDI modification of airway fluid 
albumin detected through LC-MS/MS (see Supporting Information Tables S1 and S2).
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